Financials
Financial year 2025
Virium Pharma from Aalter, company number BE0754431851, closed financial year 2025 with a result of € 60 after tax. For that financial year Virium Pharma recorded a gross margin of € 2,217 and equity of € 4,355. Compared with financial year 2024, the result moved from € 1,089 to € 60. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 2, 2026.
€ 4,355
▲ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 60
▼ 94% vs 2024
Profit after tax over the fiscal year.
€ 68,270
▼ 30% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -20,645.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 11,275
▼ 3% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,076
▼ 92% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,479
▼ 23% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 16,810 | € -14,076 | € 10,998 | € 2,217 | ▼ 80% |
| Profit after taxes | € 1,692 | € -23,487 | € 1,089 | € 60 | ▼ 94% |
| Equity | € 26,692 | € 3,206 | € 4,295 | € 4,355 | ▲ 1% |
| Total debts | € 103,664 | € 104,426 | € 118,163 | € 91,555 | ▼ 23% |
| Cash | € 78,706 | € 71,441 | € 97,188 | € 68,270 | ▼ 30% |
| Retained profit | € 1,692 | € -21,794 | € -20,705 | € -20,645 | |
| Balance sheet total | € 130,357 | € 107,632 | € 122,458 | € 95,910 | ▼ 22% |
Key figures of Virium Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to Virium Pharma?
What happened at Virium Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 60 (▼ 94% vs 2024). Source: NBB ↗
- New establishment in Aalter. KBO
- Start of the company according to the CBE. KBO
- Isabelle Huys became a director. NBB
In short
From € 1,692 profit in 2022 to € 60 profit in 2025.
Paid € 2,278 in corporate taxes since 2022.
Best year ever: 2022, with € 1,692 profit.
Management
Behind Virium Pharma is Isabelle Huys. Isabelle Huys is also behind CWINVEST.
Directors
According to the 2025 annual accounts
since 2020
Establishments
Establishment units
Physical locations of this company
Kraenepoelpad 10
9880 Aalter
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0754.431.851
- VAT number
- BE 0754.431.851
- Registered office
- Kraenepoelpad 10, 9880 Aalter
- Names & denominations
- Virium Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 September 2020
- Peppol
- Active · Active since 29 Jan 2026
- Activities · NACE
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Activiteiten van holdings
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Vervaardiging van overige farmaceutische producten
Vervaardiging van geneesmiddelen
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
+4